Recent findings revealed that SBAs are dedicated to the remission of murine colitis, as 12-ketolithocholic acid could inhibit the secretion of IL-17A by type 3 innate lymphoid cells (ILC3) through upregulating Vitamin D receptor (VDR) (Li et al.2023). Here, IL17A is linked to colitis.